This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Curious about your investment portfolio? Discover what to include to ensure a balanced and profitable mix of assets.
23,656 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Nvidia stands at a crossroads as it prepares to report Feb earnings. This article unpacks why the result could redefi...
Over the years, my approach to collecting rent transformed from paper-led reminders to a streamlined, tech-backed sys...
Cathie Wood’s approach to downturns leans into disciplined bargain hunting. This article breaks down the idea of cath...
Income investors are weighing two popular S&P 500 covered-call ETFs. This piece breaks down how SPYI and JEPI generat...
A new forecast from Goldman Sachs signals stronger near-term Tesla deliveries. This article breaks down what the upgr...
Great Elm's Q3 2026 earnings shed light on growth, margins, and capital allocation. This article breaks down the numb...
What could push the aave token could climb in the next decade? This guide breaks down the catalysts, risks, and pract...
Palantir has a unique data platform and government-commercial mix. This guide outlines how the business could evolve,...
This article dives into Black Hills’ Q1 2026 earnings transcript, translating the numbers into actionable insights. L...
Investors are eyeing Lilly for its resilient growth, strong pipeline, and shareholder-friendly strategy. This piece b...
SoFi shareholders have faced a tough year, but a pair of upbeat bank results offers a new tailwind. This article brea...